Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iressa black box sought

Executive Summary

Public Citizen requests that FDA add a black box warning to Iressa labeling "to state that the drug should be reserved for the same group of patients who were studied in the Phase II trial on which approval was based." FDA approved AstraZeneca's Iressa (gefitinib) for the treatment of advanced non-small cell lung cancer May 5 (1"The Pink Sheet" May 12, p. 3). A black box warning should communicate to "patient[s] that they may be at risk of a fatal lung disease unrelated to NSCLC," Public Citizen says in May 15 letter to Commissioner McClellan. FDA was understood to be considering a black box warning until very late in the review cycle for the drug...

You may also be interested in...



Iressa Clears FDA: Phase IV Symptom Trial Will Be First Shot At Full Approval

AstraZeneca's first chance to secure traditional approval for Iressa will be a randomized trial assessing symptom improvement in non-small cell lung cancer due to be submitted to the agency by June 2005

More Surufatinib Cheer For Chi-Med As Second NET Trial Stopped Early

Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of PFS targets in the pancreatic setting.

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

UsernamePublicRestriction

Register

PS041814

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel